Details

Autor(en) / Beteiligte

• Walsh, Douglas S.
• Eamsila, Chirapa
• Sasiprapha, Theerayuth
• Sangkharomy, Suebpong
• Khaewsathien, Pradith
• Supakalin, Panpaka
• Tang, Douglas B.
• Jarasrumgsichol, Phongsak
• Cherdchu, Chainarong
• Edstein, Michael D.
• Rieckmann, Karl H.
• Brewer, Thomas G.

Titel

Efficacy of Monthly Tafenoquine for Prophylaxis of Plasmodium vivax and Multidrug-Resistant P. falciparum Malaria

Ist Teil von

• The Journal of infectious diseases, 2004-10, Vol.190 (8), p.1456-1463

Ort / Verlag

Chicago, IL: The University of Chicago Press

Erscheinungsjahr

2004

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• We assessed monthly doses of tafenoquine for preventing Plasmodium vivax and multidrug-resistant P. falciparum malaria. In a randomized, double-blind, placebo-controlled study, 205 Thai soldiers received either a loading dose of tafenoquine 400 mg (base) daily for 3 days, followed by single monthly 400-mg doses (n = 104), or placebo (n = 101), for up to 5 consecutive months. In volunteers completing follow-up (96 tafenoquine and 91 placebo recipients), there were 22 P. vivax, 8 P. falciparum, and 1 mixed infection. All infections except 1 P. vivax occurred in placebo recipients, giving tafenoquine a protective efficacy of 97% for all malaria (95% confidence interval [CI], 82%-99%), 96% for P. vivax malaria (95% CI, 76%-99%), and 100% for P. falciparum malaria (95% CI, 60%-100%). Monthly tafenoquine was safe, well tolerated, and highly effective in preventing P. vivax and multidrug-resistant P. falciparum malaria in Thai soldiers during 6 months of prophylaxis.